Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.

Indian heart journal - 1 Jan 2000

Shetkar Sudhir S, Ramakrishnan Sivasubramanian, Seth Sandeep, Chandna Puneet, Verma Sunil K, Bhargava Balram, Bahl Vinay K

Abstract excerpt

BACKGROUND: Dual antiplatelet therapy is the cornerstone in the management of acute coronary syndromes (ACS) and prevention of stent thrombosis (ST). Genetic polymorphisms in CYP2C19 gene involved in hepatic activation of clopidogrel leads to clopidogrel non-responsiveness and may influence clinical outcomes. These polymorphisms in CYP2C19 gene and their impact on clinical outcome in coronary artery disease (CAD)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chi-Square Distribution
Share to Clopidogrel

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Coronary Angiography

Share to Coronary Disease

Share to Cyclophilins

Share to Survival Rate

Share to Tertiary Care Centers

Share to Ticlopidine

Source

Open in PubMed Open full text

Identifiers

PMID: 24581091
DOI: 10.1016/j.ihj.2013.10.001
PMCID: PMC3946470

Genes

CAD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP 450 2C19 polymorphisms in Indian patients with coronary artery disease.PMID 24581091Read ↗

Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.Semantic proximity Read ↗

Cytochrome P450 2C19 polymorphism is associated with poor clinical outcomes in coronary artery disease patients treated with clopidogrel.Semantic proximity Read ↗

Meta-analyses of the association between cytochrome CYP2C19 loss- and gain-of-function polymorphisms and cardiovascular outcomes in patients with coronary artery disease treated with clopidogrel.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

Pharmacogenomic evaluation of CYP2C19 alleles linking low clopidogrel response and the risk of acute coronary syndrome in Indians.Semantic proximity Read ↗

Cytochrome P450 2C19 polymorphism and antiplatelet therapy. Who should really be genotyped?Semantic proximity Read ↗

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.Semantic proximity Read ↗

Prevalence of CYP2C9 and CYP2C19 variants and the impact on clopidogrel efficacy in patients having CYPC19*2 variant.Semantic proximity Read ↗

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.Semantic proximity Read ↗

CYP2C19 genotype has a greater effect on adverse cardiovascular outcomes following percutaneous coronary intervention and in Asian populations treated with clopidogrel: a meta-analysis.Semantic proximity Read ↗

Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.